IndustryCompany release

Phathom Q3 revenue rises 71% to $84.7m as VOQUEZNA exclusivity dispute moves into court

🇺🇸 Phathom Pharmaceuticals, Inc. (PHAT) · Thu 29 Oct 2026

Phathom kept its full-year VOQUEZNA guidance at $310–325 million while a US court allowed it to intervene in BDR Pharmaceuticals' suit over the drug's NCE exclusivity.

Phathom Pharmaceuticals reported third-quarter 2026 net revenue of $84.7 million for VOQUEZNA (vonoprazan), its treatment for gastro-oesophageal reflux disease (GERD). The company recorded a net loss of $13.9 million for the quarter but reported positive operating cash flow. It left full-year revenue guidance unchanged at $310–325 million.

The company also said VOQUEZNA has passed 2 million prescriptions. The headline revenue figure represents growth of 71%, according to the company's announcement.

On 26 October 2026, a US federal court allowed Phathom to intervene in a suit brought by BDR Pharmaceuticals against the US Food and Drug Administration (FDA). The case concerns the new chemical entity (NCE) exclusivity granted to VOQUEZNA. The FDA has opened a public comment docket on the matter, with comments due on 23 November.

On the development side, Phathom has started a Phase 3 study of as-needed use in non-erosive GERD. It expects topline data from a Phase 2 trial in eosinophilic oesophagitis in the fourth quarter of 2026.

What it means for your team

  • Regulatory teams should note the open FDA comment docket, which closes on 23 November, as the NCE exclusivity question for VOQUEZNA is now before a federal court.
  • Market-access and competitive-intelligence teams tracking generic or follow-on entry in acid-related disorders should watch the outcome of the BDR Pharmaceuticals litigation.
  • Clinical and lifecycle planners may want to follow the Phase 3 as-needed non-erosive GERD programme and the Q4 2026 eosinophilic oesophagitis readout, which could widen the vonoprazan label landscape.

Company's press release (SEC filing): Phathom Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Phathom Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →